跳到正文
原文
MedPage Today·· 1 小时前精选AI 评分85

新型口服药物在预防遗传性血管性水肿方面效果显著

Novel Oral HAE Drug Measures Up to Injectable Options

AI 导读

一项关键的 III 期临床试验显示,新型口服药物 deucrictibant 相较安慰剂将遗传性血管性水肿(HAE)发作率降低了 83%,显著优于现有注射药物。该药物在一次每日口服后,45% 的患者在 24 周内无发作,且安全性良好。

推荐理由

研究显示新型口服药物在预防遗传性血管性水肿方面效果显著,优于现有注射药物。

正文

— Randomized trial hits the mark for reducing hereditary angioedema attack rates

November 20, 2026 • 4 min read

Prophylactic use of the novel oral bradykinin B2 receptor antagonist deucrictibant substantially reduced hereditary angioedema (HAE) attacks, a pivotal phase III trial showed.

For the primary endpoint, extended-release deucrictibant lowered the attack rate by a relative 83%, to 0.35 events per month compared with 2.06 in the placebo group (P<0.0001), reported Marc A. Riedl, MD, of the University of California San Diego, at the American College of Allergy, Asthma & Immunology annual meeting.

During the 24-week treatment period in the CHAPTER-3 trial, 45% of study drug-treated patients were attack free, compared with 3% of the placebo group (P=0.0018).

"We don't have head-to-head studies, but it is in the same ballpark of what the subcutaneous long-term prophylactic drugs have shown," Riedl told MedPage Today. "This is what we were hoping to see as investigators -- this high level of efficacy in a once-daily pill."

That's meaningful given what's been seen with the only approved targeted oral HAE prophylactic medication, berotralstat (Orladeyo), Riedl noted.

"The overall efficacy, at least in the pivotal trial for berotralstat, didn't measure up quite as well compared to some of the subcutaneous treatment options for long-term prophylaxis," he said. "So this is an effort to try to look at another oral agent that might be more effective across the population, just given that we know some patients really prefer oral medication for convenience and less burden of treatment and so forth."

Of the 85 patients in the trial, five had genetically confirmed HAE with normal C1 inhibitor levels. While two of three of these patients on deucrictibant had good results with the drug -- one had a greater than 80% reduction and the other had 100% reduction in HAE attacks -- the third patient had only a very small reduction in attack rate.

A post-hoc analysis looking at only patients with deficiency or dysfunction of C1 inhibitor levels showed an 87% reduction in attack rate with deucrictibant, a rate that Riedl said "reflects the type 1 and type 2 HAE population that every other study has reported when they report out their efficacy data for prophylaxis."

The international trial enrolled patients ages 12 years and older (mean age 39) who had at least three attacks within 3 months before screening and at least two attacks during the up to 8-week run-in period. Participants were randomly assigned 2:1 to 24 weeks of double-blind treatment with extended-release deucrictibant (40 mg once a day) or placebo.

Baseline HAE attack rate was 3.8 per month in the study drug group and 3.5 per month in the placebo group. Attack rates dropped within the first week with deucrictibant and remained lower than in the placebo group through week 24.

The relative reductions in events that required rescue medication and in moderate-to-severe HAE attacks were 83% and 77%, respectively (both P<0.0001). Nearly all patients on deucrictibant had their attack rate reduced by at least 70% (96% vs 23% on placebo, P<0.0001). The drug increased the proportion of patients who had at least a 90% reduction in attack frequency as well (65% vs 10%, P<0.0001). Deucrictibant also resulted in significantly greater improvements in mean Angioedema Quality of Life questionnaire total score and all domain scores as compared with placebo.

Riedl called the safety profile favorable overall. One treatment-emergent serious adverse event occurred in the deucrictibant group, a case of laryngeal dyskinesia that resulted in a stay in the intensive care unit for evaluation but was deemed not related to the study drug.

The sole discontinuation in the active treatment group was due to asymptomatic elevation in liver function tests. Riedl noted that this is in line with what has been seen in most of the long-term prophylactic studies with HAE medications. "These patients do sometimes have a history of fatty liver. They've been on androgens, which we know can affect their liver function," he said.

Gastrointestinal side effects seen with berotralstat were not observed with deucrictibant (1.8% vs 6.7% on placebo).

An immediate-release version of deucrictibant is also being developed for on-demand treatment of acute HAE attacks and is under review by the FDA for that indication. Riedl suggested that if the extended-release formulation were to be approved as an additional prophylactic treatment option, it could be appealing for patients who prefer oral medications over injections.

"This would potentially be an oral treatment that gives very similar efficacy in terms of preventing attacks compared to what we've seen with the subcutaneous drugs, and we don't actually have that at the moment," he said.

He pointed to the increasing options for HAE management as good for patients. "Trying to make that preventative treatment as easy, as least burdensome as we can is part of the goal," Riedl noted. "And I think this is one way to potentially do that for people -- just a once-daily medication that's portable, easy to travel with, and makes their lives easier."

来源:MedPage Today · medpagetoday.com